Lipoxen Share Discussion Threads

[buywell2] 30/6/2011 14:36

Probably because there are some buyers I reckon

decent update from Cyprotex today , and Source Bioscience are also up though like Lipoxen could well be a takeover target at current depressed levels.

[jsbach123] 30/6/2011 14:20

great movement up but puzzled as to why now, and why so sudden - good prospects but lovely determined rise.

[mikehardman] 30/6/2011 14:13

getting a shift on, for no obvious reason,
but lots of speculative reasons;
up 21% today now

[123asd] 27/6/2011 10:33

buywell2 - you might add this from the report commissioned by LPX last April:
Lipoxen's proprietary PSA-Insulin for Diabetes (Type 1 and 2) - Phase IIb expected to commence 2nd Half 2011.

[buywell2] 27/6/2011 10:10

In the UK type 2 diabetes is now to all inents and puposes 'OUT OF CONTROL'

10% of the population in the UK HAS THE DISEASE




Diabetes: Cases double in 30 years - and the outlook is bleak

Nearly one in 10 adults now has the disease, according to major study

By Kate Binns


Sunday, 26 June 2011


Roger, 61, from Watford, was diagnosed with Type 2 diabetes in 2000. He had his leg amputated below the knee after developing ischaemia (blood supply damage).


A major international study has revealed the number of adults worldwide with Type 2 diabetes has more than doubled in three decades, soaring to an estimated 347 million.


The research, published yesterday in The Lancet, shows levels have risen or at best remained unchanged in every part of the world. Over the past 30 years, the proportion of men with the condition rose from 8.3 to 9.8 per cent. The proportion of women with diabetes increased from 7.5 to 9.2 per cent.

Professor Majid Ezzati from Imperial College London, who led the research, says that the figures don't reflect the generations of overweight children and young adults who have yet to reach middle age. "We are not at the peak of this wave yet," he said. "And unlike high blood pressure and cholesterol, we still don't have great treatments for [Type 2] diabetes."

Unlike Type 1 diabetes, which is typically diagnosed in childhood and is due to the body's inability to produce insulin, Type 2 is linked to obesity and tends to strike in middle age.

Much of the increase in Type 2 diabetes can be attributed to ageing populations and by population growth, but part of it has also been fuelled by rising obesity rates. The study, the largest of its kind, was co-led by Dr Goodarz Danaei from the Harvard School of Public Health, in collaboration with the World Health Organisation and a number of other institutions.

Blood sugar measurements from 2.7 million participants aged 25 or over from around the world were examined. Professor Ezzati and his colleagues also scrutinised more than 150 national health surveys and studies that tracked Type 2 diabetes in adults over 25 in 199 countries and territories. They used modelling to estimate cases for another 92 countries. With numbers going up almost everywhere, experts said the disease has now become a global crisis. Countries in which the numbers rose fastest include Cape Verde, Samoa, Saudi Arabia, Papua New Guinea and the US. Prevalence rose most sharply in the Pacific Island nations, with the Marshall Islands being the diabetes capital of the world. One in three women and one in four men there have diabetes.

In the UK and elsewhere in Western Europe, there was only a slender rise, despite widening waistlines. Levels were lowest in the Netherlands, Austria and France. Experts admitted they were uncertain why and suggested several theories, including worse detection of the disease, genetic differences, or perhaps that Europeans were better at getting the overweight to reduce their risk factors through public campaigns on healthy eating, smoking and fitness.

Women in Singapore, France, Italy and Switzerland remained relatively slim, with almost no change in diabetes rates. Numbers also stayed flat in sub-Saharan Africa, central Latin America and rich Asian countries.

While increasing lifespan and body weight were acknowledged as two of the strongest factors influencing diabetes rates, especially among women, other factors exist. Genetic factors, nutrition in the womb and after birth, diet and physical activity are also important. South Asians were cited as an example of ethnic genetic factors at play. Men in southern Asia had the second smallest change in BMI (body mass index) of the 21 sub-regional studies, yet the sixth highest rate in mean FPG ("fasting plasma glucose") used to diagnose diabetes. Southern Asian women had the fourth smallest BMI change but the sixth largest rise in FPG, about the same as in high-income North America where female BMI increased three times as much.

Doctors warned of the higher susceptibility of certain groups such as Asians, blacks and Hispanics to diabetes. "Other ethnicities don't have to be as obese as people of European descent to get diabetes," said Dr Aaron Cypess, a physician at Joslin Diabetes Center not linked to the Lancet study. "It may be, for example, that Indians and Chinese store their fat in more dangerous places, like a pot belly," he said, putting forward the theory that this kind of abdominal fat can send out hormones to speed up diabetes.

Between 85 and 95 per cent of all diabetes cases fall into the lifestyle-related Type 2 category. Type 1, or insulin-dependent, diabetes is a separate auto-immune disorder and much less common. This week ,a study gave hope to the 2.9 million Type 2 diabetes sufferers in the UK. Researchers at Newcastle University discovered that an extreme eight-week diet of 600 calories a day can reverse the condition in newly diagnosed people. The study included 11 people following a strict low-calorie diet resulting in pre-breakfast blood sugar levels returning to normal within just a week. Results showed that reduced fat levels in the pancreas and liver helped insulin production return to normal. More research is planned to see whether the reversal is permanent.

The overall outlook, however, is bleak. Hyperglycaemia and diabetes are responsible for more than three million deaths worldwide every year, through both direct clinical complications and indirect health problems such as heart disease and strokes. "Diabetes may well become the defining issue of global health for the next decade," said Professor Ezzati.

Dr Danaei said: "Unless we develop better programmes for detecting people with elevated blood sugar and helping them to improve their diet and physical activity, diabetes will continue to impose a major burden on health systems around the world."

Case studies...

Surjeet Soin; Accountant

Surjeet, 66, an accountant from Luton, was diagnosed with Type 2 diabetes in 1995. It was no surprise when the doctor came back with his glucose test results

"I had all the typical symptoms – I was overweight and had been inactive for years," he says. He started medication and overhauled his lifestyle. He gave up alcohol and took up walking. "I realised I had to do something," he adds. His charity work for Diabetes UK has taken him to the volcanic mountains in Ecuador and the Everest base camp. "I have done the three peaks in Yorkshire every year for many years. It helps me maintain my health." Every three months he goes for a blood test. He runs a local support group offering advice to other diabetics and also participates in Diabetes UK awareness days. Surjeet says he believes patients need to be educated. "It is not a big part of my life but it is something I have to deal with."

Kate Baumber; Development manager

Kate, 42, from Woodhall Spa, Lincolnshire, was diagnosed with Type 1 diabetes aged nine

"Back then insulin injections involved stainless steel needles," she says. It impacted enormously on her life: as a teen she suffered numerous hypoglycaemic episodes (when blood sugar levels fall too low) and struggled during pregnancy. Kate's insulin pump has changed her life immeasurably. "I am a lot more confident, don't have to inject and there are no more comas."

Roger Lewis; Retired drama teacher

Roger, 61, from Watford, was diagnosed with Type 2 diabetes in 2000. He had his leg amputated below the knee after developing ischaemia (blood supply damage)

"I assumed medication was enough. The amputation was one of the most horrible experiences, but I would be dead if I had continued as I was." He no longer smokes, and eats healthily and goes to the gym. Roger has also been invited by Watford General Hospital to talk to prospective amputees, to show them "life isn't over".

[buywell2] 27/6/2011 10:01

A western partner can't be far away


HEALTH INDUSTRY JUNE 27, 2011 Diabetes Cases Double to 347 Million Article

By GAUTAM NAIK
The number of adults with diabetes has doubled world-wide over the last three decades to nearly 350 million and increased nearly threefold in the U.S., a sign that the epidemic will impose an ever-greater cost burden on health systems.

The latest calculation, based on a study published in the British journal Lancet, found that the number of adult diabetics jumped to 347 million from 153 million in 1980.

According to the study, the U.S. had 24.7 million diabetics in 2008, nearly triple the level of three decades ago. The estimate includes people afflicted with type-1 diabetes, which is a disorder of the body's immune system, as well as the far more common type-2 diabetes, a chronic disorder marked by high levels of sugar in the blood.

While about 70% of the increase was attributed to population growth and aging, the balance was linked to changing diets, rising obesity and growing rates of physical inactivity.

"Diabetes is a long-lasting and disabling condition, and it's going to be the largest cost for many health systems," said Majid Ezzati, a professor of global environmental health at Imperial College London and a lead author of the study.

Many public-health experts consider the rise in diabetes to be more worrying than the rise in high blood pressure rates and cholesterol levels. While rates for those conditions have dropped in some parts of the world, type-2 diabetes is becoming more common almost everywhere, and is increasingly showing up in children.

There are effective drugs for high blood pressure and cholesterol, but it's harder to prevent or treat diabetes. The condition is more debilitating for many patients: It occurs when the cells of the body cannot take up sugar in the form of glucose, and can lead to kidney failure, blindness or amputation of limbs.

In the U.S., the total cost of diagnosed diabetes was estimated at $174 billion in 2007, according to the American Diabetes Association.

The latest study, funded by the Bill & Melinda Gates Foundation and the World Health Organization, represents a more comprehensive calculation of diabetes prevalence than some previous estimates. The 347 million estimate in Lancet, for example, is nearly 25% higher than an estimate of 285 million adult diabetics reported in a 2009 study.

Doctors commonly test for diabetes by measuring the level of glucose in the blood at least eight hours after a person ate the last meal. A higher-than-normal level is effectively a diagnosis of the condition.

The Lancet study incorporated glucose measurements from 2.7 million adults across the world. The proportion of diabetic men rose to 9.8% in 2008 from 8.3% in 1980. The proportion of women with the disease rose to 9.2% from 7.5% over the same time period.

About 138 million adult diabetics live in China and India and another 36 million in the U.S. and Russia. Among high-income countries, the increase in diabetes was highest in North America but relatively small in Western Europe.

The picture isn't clear cut, however. For example, while diabetes increased slightly in Japan over the three decades, levels stayed flat in South Korea and Thailand, which Dr. Ezzati attributes to healthier lifestyles in the latter two countries.

Similarly, while the increase in the average American's body mass index-a measure of body fat-was much greater than the equivalent rise in India, the rise in diabetes levels was similar in both populations.

Dr. Ezzati says this puzzle could be explained by what's known as the Barker hypothesis: when a fetus is deprived of adequate nutrients in the womb, it may become predisposed to various ailments in later life, including diabetes.

[the_doctor] 21/6/2011 08:19

'correctly'

lol. So it's fine to just ignore the down trends with the stocks you own Buywell!
or to ignore the proximity to a cash raising with Lipoxen!


'commissioned research company' - 'lol'


I wont post anything negative here or on your other 6 key stocks.
but only on the condition you stop going out of your way to do that with mine.

Up to you buywell.

[buywell2] 21/6/2011 08:11

It is evident that not everyone can read charts correctly



note the blue lines show higher highs made in the last 3 years

Lipoxen is pleased to announce the appointment of Growth Equities and Company Research, the commissioned research company who have today published a Research note entitled "Lipoxen: Initiate Coverage at 10.5p with a Target Price of 30.7p and Recommendation of Buy".

[the_doctor] 21/6/2011 07:55

'I will let others speak on my behalf ...'

because you cant justify the fact that totally unprovoked, you headed off with the sole purpose of deramping several stocks I own.

So Buywell, tell me is it:
a) that you're worried about Lipoxen, so deramp other biotechs hoping to scare holders out into your beloved stock
b) you're simply an inconsiderate pr!ck

As I had to last time buywell, I will say this.
Quit posting your silly childish deramping charts and lies on other stocks and I wont feel the need to return here to warn people of the coming cash call here.
And yes, you posted lies, suggesting OXB would need to raise funds soon - when it just has and has a much bigger cash runway than your beloved Lipoxen.

I honestly dont know what you're hoping to acheive.
EVERY time you continue to post provokative deramps on other bio threads, I will return to here and your other stocks to point out the negatives.
I will also repeatedly post this chart below.





Lipoxen needs a deal soon just to avoid a dilutive fundraising.
It has only limited scope for getting a deal.
PRM, OXB and SLN have a longer cash runway than Lipoxen and in the case of PRM and OXB are IMO on the verge of large deals that will cause the share price to double.


YOUR CALL Buywell. You started this silliness by going out of your way to deramp my stocks.

[the_doctor] 20/6/2011 15:25

Buywell, what's your problem?? Seriously?

I've seen you go out of your way to recently deramp those three stocks, with lies about fundraising [when Lipoxen has much less cash!], naive childish charts [when Lipoxen has exactly the same chart]

Nobody in any way provoked you, but off you go with your pathetic deramps.
I can guess you're doing it in the hope that by deramping other stocks, you'll attract buyers to your own struggling set of companies.

you're a desperate tw@t, you really are.

[buywell2] 17/6/2011 16:28

I know the doc has been keen on OXB ... SLN and PRM

If he gets keen on this , then I'm worried

[123asd] 16/6/2011 21:18

holly_dog - yes, the Chairman's statement is full of broad hints about where future funding is going to come from. It's unfortunate that apparently negotiations have dragged on for so long, but he also intimates they may be drawing to a conclusion.
Note also that in the Notice of AGM document on the LPX website there is provision for a vote to allow two small rights issues. Since these are so modest - barely enough for a few months' operations at their present cash burn rate - I assume the provision is there as cautionary insurance against said negotiations breaking down - a fairly standard thing to do in the circumstances.

[holly_dog] 16/6/2011 19:41

lol sounds like a good board

[the_doctor] 16/6/2011 18:56

holly_dog

I'd suggest doing your own research. You'll get lies from the desperate ramper buywell and others will just dismiss anything negative.

[holly_dog] 16/6/2011 17:00

that's always my big question - do they have funding to get to results

according to annual report it suggests they do, although with a caveat (see last paragraph pg3, first paragraph pg 4, and first paragraph pg 6)

would appreciate if any holders could shed more light on their funding position

[the_doctor] 16/6/2011 16:44

nope, dont hold and havent looked into it. I'd wait and see if they have to raise cash personally, but maybe they have enough to get deal money in?

[holly_dog] 16/6/2011 14:59

doctor - interesting seeing you here. do you hold? have just started from scratch researching this company. any links etc appreciated

[the_doctor] 15/6/2011 15:58

'There was a definite shortage of shares this week which prompted me to change my mind and make a small top up at 9.25p.
Part of it is a bit of sector rotation in the market I think which favours "defensives" like pharmas'

while big pharmas have historically been defensive, loss-making small caps dont tend to be
although pharmas do of course continue to spend money, much of it going to small caps

IMO big pharmas are no longer defensive - with healthcare budgets stretched, cheap alternative generic drugs, products going off patent and R&D productivity waning, they're certainly less defensive now

[123asd] 15/6/2011 15:28

the_doctor filtered. Please take your squabbles elsewhere.